<p>擬議的交易仍需進行盡職調查、簽署最終協議、獲得監管批准以及符合納斯達克上市要求；在此階段，ABL S.A. 對 ABL Diagnostics 的控制權沒有變化。</p>
<p>法國 WOIPPY--（商業資訊）-- 監管新聞：</p>
<p>ABL Diagnostics（Euronext: ABLD - ISIN: FR001400AHX6）通知其股東和市場，其控股股東 Advanced Biological Laboratories S.A.（“ABL S.A.”）與 ProPhase Labs, Inc.（“ProPhase，” 納斯達克：PRPH）已簽署一份非約束性意向書（“LOI”），關於擬議的反向合併，屆時 ABL 將成為合併公司的大股東。</p>
<p>該意向書是初步的，不構成完成交易的義務，除非是通常的保密和費用條款。該提案仍需進行盡職調查、談判和簽署最終協議、獲得監管批准、遵守納斯達克上市要求以及其他通常的成交條件。各方的目標是在 60-90 天內簽署最終協議。</p>
<p>根據現有信息，擬議的交易不會影響 ABL S.A. 對 ABL Diagnostics 的控制權，也不會觸發強制性收購門檻。儘管如此，ABL Diagnostics 將與其顧問審查所有方面，並在適當情況下通知 AMF 並尋求豁免。</p>
<p>在美國，如果發生控制權變更和/或發行 20% 或更多股份，交易可能需要 ProPhase 股東的批准。ProPhase 仍需負責遵守納斯達克/SEC 規則。</p>
<p>如果未達成協議。如果未簽署最終協議，各方將繼續獨立運營；意向書並不構成完成交易的義務。</p>
<p><strong>MAR 通知 — 內部信息</strong></p>
<p>本新聞稿包含根據歐盟法規（EU）第 596/2014 號第 17 條定義的內部信息。ABL Diagnostics 儘快披露此類信息。如決定延遲披露，將根據適用法規和指導方針處理並通知 AMF。本發佈將在 ABL Diagnostics 網站的 “監管信息” 部分存檔至少 5 年。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本發佈可能包含基於假設的前瞻性聲明，並受到可能導致實際結果顯著不同的風險和不確定性的影響。ABL Diagnostics 不承擔更新的義務，除非法律要求。</p>
<p><strong>關於 ABL Diagnostics（ABLD）</strong></p>
<p>ABL Diagnostics（ABLD）是一家國際公司，專注於創新的分子生物學檢測和全球解決方案，服務於其客户：</p>
<ul>
<li>分子聚合酶鏈反應（PCR）檢測 – UltraGene，以及</li>
<li>通過 DNA 測序進行基因分型 – DeepChek®。</li>
</ul>
<p>ABL Diagnostics 通過自己的銷售團隊和活躍於所有大洲的獨家分銷商網絡在全球市場銷售其全部產品。ABL Diagnostics 的客户包括學術臨牀病理實驗室、私人蔘考實驗室以及希望實施創新和穩健的微生物內容的研究人員。</p>
<p>自 2025 年下半年以來，ABL Diagnostics 通過內部戰略協議營銷其姐妹公司 CDL Pharma 的產品和服務。</p>
<p><strong>不斷擴展的微生物學產品組合：</strong></p>
<ul>
<li>HIV – 藥物耐藥性檢測，包括全基因組試劑盒。</li>
<li>SARS-CoV-2、結核病、乙型和丙型肝炎 – 先進的檢測解決方案。</li>
<li>微生物組和分類 – 基於 16s/18s RNA 的分析。</li>
<li>其他病毒和細菌靶標 – 綜合分子檢測。</li>
</ul>
<p><strong>綜合解決方案</strong></p>
<ul>
<li>實時綜合 PCR 檢測</li>
<li>Nadis® – 在法國 200 多家醫院用於 HIV 和肝炎管理的患者醫療記錄。</li>
<li>MediaChek® – 臨牀樣本採集試劑盒。</li>
</ul>
<p>ABL Diagnostics 總部位於 Woippy，是一家在巴黎 Euronext 受監管市場 B 類上市的公眾有限公司（Euronext: ABLD – ISIN: FR001400AHX6）。這些分子生物學產品產生經常性收入，並涵蓋微生物學中最大的應用組合之一。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg5ODQ3OTVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg5ODQ3OTVyMQ"/></p>
<p>查看商業資訊上的源版本：https://www.businesswire.com/news/home/20251218984795/en/</p>
<p><strong>ABL Diagnostics SA</strong></p>
<p>股份公司，註冊資本為 1,611,465.60 歐元</p>
<p>總部：72C route de Thionville - 57140 WOIPPY</p>
<p>552 064 933 R.C.S. METZ</p>
<p>電話：+33 (0) 7 83 64 68 50</p>
<p>電子郵件：<strong>info@abldiagnostics.com</strong></p>
<p><strong>https://www.abldiagnostics.com/</strong></p>
<p>來源：ABL Diagnostics</p>

PRPH

<p>ABL Diagnostics 宣佈其控股股東 ABL S.A. 與 ProPhase Labs 之間達成了一份非約束性的意向書，擬進行反向合併。該交易需經過盡職調查、監管審批和納斯達克的要求。ABL S.A. 將成為合併後公司的主要股東。該意向書為初步文件，未對最終達成交易產生任何義務，目標是在 60-90 天內達成最終協議。目前該交易不會影響 ABL S.A. 對 ABL Diagnostics 的控制權</p>

<p><em>The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.’s control over ABL Diagnostics at this stage.</em></p>
<div class="lb-trans"><p>擬議的交易仍需進行盡職調查、簽署最終協議、獲得監管批准以及符合納斯達克上市要求；在此階段，ABL S.A. 對 ABL Diagnostics 的控制權沒有變化。</p>
</div><p>WOIPPY, France--(BUSINESS WIRE)--Regulatory News:</p>
<div class="lb-trans"><p>法國 WOIPPY--（商業資訊）-- 監管新聞：</p>
</div><p>ABL Diagnostics (Euronext: ABLD - ISIN: FR001400AHX6) informs its shareholders and the market that Advanced Biological Laboratories S.A. (“ABL S.A.”), its controlling shareholder, and ProPhase Labs, Inc. (“ProPhase,” Nasdaq: PRPH) have signed a non‑binding letter of intent (the “LOI”) regarding a proposed reverse merger pursuant to which ABL would become the majority owner of the combined company.</p>
<div class="lb-trans"><p>ABL Diagnostics（Euronext: ABLD - ISIN: FR001400AHX6）通知其股東和市場，其控股股東 Advanced Biological Laboratories S.A.（“ABL S.A.”）與 ProPhase Labs, Inc.（“ProPhase，” 納斯達克：PRPH）已簽署一份非約束性意向書（“LOI”），關於擬議的反向合併，屆時 ABL 將成為合併公司的大股東。</p>
</div><p>The LOI is preliminary and creates no obligation to consummate a transaction, other than customary confidentiality and expense provisions. The proposal remains subject to due diligence, negotiation and execution of definitive agreements, regulatory approvals, compliance with Nasdaq listing requirements, and other customary closing conditions. The parties are targeting an indicative 60–90‑day timeframe to execute definitive agreements.</p>
<div class="lb-trans"><p>該意向書是初步的，不構成完成交易的義務，除非是通常的保密和費用條款。該提案仍需進行盡職調查、談判和簽署最終協議、獲得監管批准、遵守納斯達克上市要求以及其他通常的成交條件。各方的目標是在 60-90 天內簽署最終協議。</p>
</div><p>Based on the information available, the contemplated transaction does not affect ABL S.A.’s control over ABL Diagnostics and does not trigger the mandatory offer threshold. ABL Diagnostics will nevertheless review all aspects with its advisors and, where appropriate, will notify the AMF and seek a waiver.</p>
<div class="lb-trans"><p>根據現有信息，擬議的交易不會影響 ABL S.A. 對 ABL Diagnostics 的控制權，也不會觸發強制性收購門檻。儘管如此，ABL Diagnostics 將與其顧問審查所有方面，並在適當情況下通知 AMF 並尋求豁免。</p>
</div><p>In the United States, the transaction may require approval by ProPhase shareholders in the event of a change of control and/or an issuance of 20% or more. ProPhase remains responsible for compliance with Nasdaq/SEC rules.</p>
<div class="lb-trans"><p>在美國，如果發生控制權變更和/或發行 20% 或更多股份，交易可能需要 ProPhase 股東的批准。ProPhase 仍需負責遵守納斯達克/SEC 規則。</p>
</div><p>If no agreement is reached. If no definitive agreements are executed, each party will continue operating independently; the LOI does not create an obligation to consummate a transaction.</p>
<div class="lb-trans"><p>如果未達成協議。如果未簽署最終協議，各方將繼續獨立運營；意向書並不構成完成交易的義務。</p>
</div><p><strong>MAR notices — Inside information</strong></p>
<div class="lb-trans"><p><strong>MAR 通知 — 內部信息</strong></p>
</div><p>This press release contains inside information within the meaning of Article 17 of Regulation (EU) No. 596/2014 (“MAR”). ABL Diagnostics discloses such information as soon as possible. Any delay in disclosure, if decided, would be handled and notified to the AMF in accordance with applicable regulation and guidance. This release will be archived for at least 5 years in the ‘Regulatory Information’ section of ABL Diagnostics’ website.</p>
<div class="lb-trans"><p>本新聞稿包含根據歐盟法規（EU）第 596/2014 號第 17 條定義的內部信息。ABL Diagnostics 儘快披露此類信息。如決定延遲披露，將根據適用法規和指導方針處理並通知 AMF。本發佈將在 ABL Diagnostics 網站的 “監管信息” 部分存檔至少 5 年。</p>
</div><p><strong>Forward‑looking statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This release may include forward‑looking statements based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially. ABL Diagnostics undertakes no obligation to update, except as required by law.</p>
<div class="lb-trans"><p>本發佈可能包含基於假設的前瞻性聲明，並受到可能導致實際結果顯著不同的風險和不確定性的影響。ABL Diagnostics 不承擔更新的義務，除非法律要求。</p>
</div><p><strong>About ABL Diagnostics (ABLD)</strong></p>
<div class="lb-trans"><p><strong>關於 ABL Diagnostics（ABLD）</strong></p>
</div><p>ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:</p>
<div class="lb-trans"><p>ABL Diagnostics（ABLD）是一家國際公司，專注於創新的分子生物學檢測和全球解決方案，服務於其客户：</p>
</div><ul>
<li>Molecular polymerase chain reaction (PCR) detection – UltraGene, and</li>
<li>Genotyping by DNA sequencing – DeepChek®.</li>
</ul>
<div class="lb-trans"><ul>
<li>分子聚合酶鏈反應（PCR）檢測 – UltraGene，以及</li>
<li>通過 DNA 測序進行基因分型 – DeepChek®。</li>
</ul>
</div><p>ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.</p>
<div class="lb-trans"><p>ABL Diagnostics 通過自己的銷售團隊和活躍於所有大洲的獨家分銷商網絡在全球市場銷售其全部產品。ABL Diagnostics 的客户包括學術臨牀病理實驗室、私人蔘考實驗室以及希望實施創新和穩健的微生物內容的研究人員。</p>
</div><p>ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.</p>
<div class="lb-trans"><p>自 2025 年下半年以來，ABL Diagnostics 通過內部戰略協議營銷其姐妹公司 CDL Pharma 的產品和服務。</p>
</div><p><strong>An expanding portfolio of microbiology products:</strong></p>
<div class="lb-trans"><p><strong>不斷擴展的微生物學產品組合：</strong></p>
</div><ul>
<li>HIV – Drug resistance testing, including a whole genome kit.</li>
<li>SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.</li>
<li>Microbiome and taxonomy – 16s/18s RNA-based analyses.</li>
<li>Other viral and bacterial targets – Comprehensive molecular assays.</li>
</ul>
<div class="lb-trans"><ul>
<li>HIV – 藥物耐藥性檢測，包括全基因組試劑盒。</li>
<li>SARS-CoV-2、結核病、乙型和丙型肝炎 – 先進的檢測解決方案。</li>
<li>微生物組和分類 – 基於 16s/18s RNA 的分析。</li>
<li>其他病毒和細菌靶標 – 綜合分子檢測。</li>
</ul>
</div><p><strong>Integrated Solutions</strong></p>
<div class="lb-trans"><p><strong>綜合解決方案</strong></p>
</div><ul>
<li>Real-time syndromic PCR tests</li>
<li>Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.</li>
<li>MediaChek® – Clinical Sample Collection Kits.</li>
</ul>
<div class="lb-trans"><ul>
<li>實時綜合 PCR 檢測</li>
<li>Nadis® – 在法國 200 多家醫院用於 HIV 和肝炎管理的患者醫療記錄。</li>
<li>MediaChek® – 臨牀樣本採集試劑盒。</li>
</ul>
</div><p>ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.</p>
<div class="lb-trans"><p>ABL Diagnostics 總部位於 Woippy，是一家在巴黎 Euronext 受監管市場 B 類上市的公眾有限公司（Euronext: ABLD – ISIN: FR001400AHX6）。這些分子生物學產品產生經常性收入，並涵蓋微生物學中最大的應用組合之一。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTg5ODQ3OTVyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251218984795r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251218984795/en/</p>
<div class="lb-trans"><p>查看商業資訊上的源版本：https://www.businesswire.com/news/home/20251218984795/en/</p>
</div><p><strong>ABL Diagnostics SA</strong></p>
<div class="lb-trans"><p><strong>ABL Diagnostics SA</strong></p>
</div><p>Société anonyme au capital de 1 611 465,60 euros</p>
<div class="lb-trans"><p>股份公司，註冊資本為 1,611,465.60 歐元</p>
</div><p>Headquarters : 72C route de Thionville - 57140 WOIPPY</p>
<div class="lb-trans"><p>總部：72C route de Thionville - 57140 WOIPPY</p>
</div><p>552 064 933 R.C.S. METZ</p>
<div class="lb-trans"><p>552 064 933 R.C.S. METZ</p>
</div><p>Tel : +33 (0) 7 83 64 68 50</p>
<div class="lb-trans"><p>電話：+33 (0) 7 83 64 68 50</p>
</div><p>Email : <strong>info@abldiagnostics.com</strong></p>
<div class="lb-trans"><p>電子郵件：<strong>info@abldiagnostics.com</strong></p>
</div><p><strong>https://www.abldiagnostics.com/</strong></p>
<div class="lb-trans"><p><strong>https://www.abldiagnostics.com/</strong></p>
</div><p>Source: ABL Diagnostics</p>
<div class="lb-trans"><p>來源：ABL Diagnostics</p>
</div>

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger | PRPH Stock News

ABL Diagnostics 向市場通報 ABL S.A.與 Prophase Labs（納斯達克代碼：PRPH）之間擬議反向合併的非約束性意向書 | PRPH 股票新聞